1728-5917
1728-5917
S1728-59172022000200205
10.35663/amp.2022.392.2376
Perú
Perú
Peru
Perú
Perú
Perú
Perú
Perú
Peru
Perú
00
04
2022
00
04
2022
39
2
205
215
[
DMD Care Considerations Working Group
2018
17
3
3
251-67
]
[
2018
142
Suppl 2
Suppl 2
S5-S16
]
[
2017
12
1
1
79
]
[
2013
8
1
1
]
[
al-Dahhak R.Gastier-Foster J.Kneile K.Dunn DM.Duval B.Aoyagi A.Hamil C.Mahmoud M.Roush K.Bird L.Rankin C.Lilly H.Street N.Chandrasekar R.Weiss RB
2012
71
3
3
304-13
]
[
2014
24
6
6
482-91
]
[
2009
132
11
11
3175-86
]
[
2018
6
6
6
873-86
]
[
2017
358
j4008
]
[
Cochrane Bias Methods GroupCochrane Statistical Methods Group
2011
343
d5928
]
[
2014
]
[
QUADAS-2 Group
2011
155
8
8
529-36
]
[
2018
23
2
2
60-3
]
[
2013
66
7
7
726-35
]
[
2013
66
7
7
719-25
]
[
2018
8
1
1
31
]
[
1999
190
1
1
143-51
]
[
2020
7
3
3
231-46
]
[
2013
70
23
23
4585-602
]
[
2017
27
2
2
107-14
]
[
2004
23
5
5
413-9
]
[
2000
18
5
5
561-4
]
[
2015
3
4
4
158-65
]
[
2018
25
3
3
404-32
]
[
2019
491
66-73
]
[
2013
95
12
12
1057-61
]
[
1991
48
4
4
383-8
]
[
1989
320
24
24
1592-7
]
[
2020
]
[
PTC124-GD-007-DMD Study GroupACT DMD Study GroupClinical Evaluator Training Groups
2020
9
14
14
973-84
]
[
CINRG Duchenne Natural History Investigators
2020
9
5
5
341-60
]
[
2017
27
1
1
1-3
]
[
2017
11
533-45
]
[
2020
80
3
3
329-33
]
[
2019
]
[
2015
36
4
4
395-402
]
[
SKIP-NMD Study Group
2020
94
21
21
e2270-e82
]
[
2020
56
8
8
491-504
]
[
2020
11
8
8
837
]
[
FDA
2020
]